Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2008

View Archived Issues

Novel class of bacterial topoisomerase II inhibitors reported by Pharmacia

Indomethacin silicon-amide derivatives may have improved physiological activity

First-in-class inhibitors of EWS-FLI1 protein potentially effective against Ewing's sarcoma

Johnson & Johnson's R-231857 shows benefit in a model of cognitive impairment in healthy men

Lilly to fund rodent studies of Corcept's selective GRII receptor antagonist CORT-108297

UNC to conduct phase IIa clinical trial of Discovery's KL-4 surfactant in CF

Recent GlaxoSmithKline patent claims new compounds for cardiovascular conditions

Mutual submits NDA to FDA for antihyperlipidemic drug MPC-028

U.S. Army to provide Neuren with additional funding for phase II trial of NNZ-2566

Protox completes enrollment in phase II trial of PRX-302 in BPH

Novel antipsychotic profile described for Pierre Fabre's F-16615

Novel PAR1 antagonists discovered at Pierre Fabre

Ardea Biosciences describes discovery of MEK inhibitor RDEA-119

Structure-activity relationship analysis of novel IKKbeta inhibitors leads to AS-1950930

Polidocanol sclerotherapy product is effective in varicose vein treatment

Sumatriptan oral spray effective in migraine headache relief at lower dose than tablets

Palifosfamide studied in new phase II trial for soft tissue sarcoma

iCo-009 advances towards clinic

MDRNA awarded further funding for research in RNA inhibition of influenza

GMI-1070 enters clinic for vaso-occlusive crisis of sickle cell disease

SARcode begins phase I trial for LFA-1 product candidate

Histalean begins phase II female obesity study

Progenics starts phase I prostate cancer study of PSMA antibody-drug conjugate

New treatment options for urinary incontinence described in recent Toray patent

BioSante clinical results for Pill-Plus triple hormone therapy

Pharmasset reports preliminary results of R-7128 proof-of-concept study in HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 11, 2025.
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld Asia
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty
BioWorld
With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...